Objective To identify baseline magnetic resonance imaging (MRI) features associated with treatment response in post-traumatic olfactory dysfunction (PTOD) and to develop an exploratory MRI-based risk score. Methods This single-center retrospective cohort study included 41 patients with PTOD and 41 age- and sex-matched healthy controls. Olfactory bulb (OB) volume, morphology, and integrity, olfactory sulcus depth, and structural lesions in olfactory-related cortical regions were assessed on MRI. Olfactory function was evaluated using the Sniffin’ Sticks test, and treatment response was defined as an increase of ≥5.5 points in the Threshold-Discrimination-Identification score. Least absolute shrinkage and selection operator (LASSO) regression was used to select MRI features for model development, from which a simplified integer-based scoring system was derived. Results Compared with healthy controls, patients with PTOD had a shallower left olfactory sulcus and lower proportions of convex OB morphology bilaterally. After a median follow-up of 8 months, 16 of 41 patients (39.0%) met the treatment-response criterion. Three MRI features were retained in the LASSO model: left OB integrity, left orbital gyrus injury, and right temporal lobe injury. The resulting model had an apparent area under the receiver operating characteristic curve (AUC) of 0.885 (95% confidence interval [CI], 0.787–0.983). Full-pipeline internal validation yielded a stratified ten-fold cross-validated AUC of 0.733 (95% CI, 0.564–0.901) and a bootstrap optimism-corrected AUC of 0.725. The simplified three-factor scoring system had an apparent AUC of 0.869 (95% CI, 0.761–0.977) and a bootstrap bias-corrected AUC of 0.867, with treatment response rates of 75.0%, 50.0%, and 5.3% in the low-, intermediate-, and high-risk groups, respectively. The empirical MRI scoring scheme had an apparent AUC of 0.805 (95% CI, 0.662–0.926); the difference between the two scoring systems was not statistically significant (DeLong p = 0.079). Conclusion Baseline structural MRI features were associated with treatment response in PTOD. The exploratory three-factor MRI-based score showed potential for risk stratification within this cohort, but prospective external validation is required before clinical application.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: